“Efficacy and safety of liraglutide in pediatric Obesity:A systematic review and meta analysis of randomized controlled trials”

Q2 Medicine

Obesity Medicine Pub Date : 2025-03-28 DOI:10.1016/j.obmed.2025.100605

Abdullah Afridi , Fathimathul Henna , Umaima Cheema , Ayesha Sehar , Muhammad Fakhir Iftikhar Rana , Areej Dar , Bibi Hafza , Iqra khan , Laiba Ali Khan , Aafeen Mujeeb , Ayesha Khalid Sheikhani , Insha Habib , Muhammad Abdullah Ali , Momina Ali , Mizhgan Abid , Ansar Hussain

{"title":"“Efficacy and safety of liraglutide in pediatric Obesity:A systematic review and meta analysis of randomized controlled trials”","authors":"Abdullah Afridi , Fathimathul Henna , Umaima Cheema , Ayesha Sehar , Muhammad Fakhir Iftikhar Rana , Areej Dar , Bibi Hafza , Iqra khan , Laiba Ali Khan , Aafeen Mujeeb , Ayesha Khalid Sheikhani , Insha Habib , Muhammad Abdullah Ali , Momina Ali , Mizhgan Abid , Ansar Hussain","doi":"10.1016/j.obmed.2025.100605","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Liraglutide, a GLP-1 receptor agonist, has been explored for its potential benefits in managing paediatric obesity. This meta-analysis aims to assess the efficacy and safety of liraglutide compared to placebo in this paediatric population with obesity.</div></div><div><h3>Methods</h3><div>We systematically searched PubMed, Embase, and Cochrane for randomized controlled trials (RCTs) on liraglutide in children with obesity. Five studies with 247 participants were included. Primary outcomes included changes in BMI SDS, BMI, and body weight, and secondary outcomes included fasting serum insulin, HbA1c, fasting plasma glucose, SBP, DSP, and safety outcomes.</div></div><div><h3>Results</h3><div>The meta-analysis included five randomized controlled trials with 247 participants evaluating liraglutide in pediatric obesity. Liraglutide significantly reduced BMI SDS, with a pooled mean difference of −0.17 (p = 0.003), BMI (mean difference: 1.28, p = 0.0008), and body weight (mean difference: 1.83, p = 0.03). Secondary outcomes showed significant reductions in fasting serum insulin levels (pooled effect size: 0.39, p < 0.00001), but no significant effects were observed for DSP (p = 0.29), fasting plasma glucose (p = 0.07), HbA1c (p = 0.09), or systolic blood pressure (p = 0.09). Safety analysis revealed a higher incidence of adverse events in the treatment group (risk ratio: 1.25, p = 0.18), but no significant differences were found in serious adverse events or adverse events leading to therapy discontinuation.</div></div><div><h3>Conclusions</h3><div>Liraglutide is effective in reducing BMI SDS, BMI, and body weight in pediatric obesity. While it significantly reduces fasting serum insulin levels, other secondary outcomes did not show significant changes. The safety profile of liraglutide shows a higher incidence of adverse events but no increase in serious adverse events or discontinuation rates. These findings support liraglutide's role as an effective and manageable treatment option for pediatric obesity.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"55 ","pages":"Article 100605"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2451847625000259","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Liraglutide, a GLP-1 receptor agonist, has been explored for its potential benefits in managing paediatric obesity. This meta-analysis aims to assess the efficacy and safety of liraglutide compared to placebo in this paediatric population with obesity.

Methods

We systematically searched PubMed, Embase, and Cochrane for randomized controlled trials (RCTs) on liraglutide in children with obesity. Five studies with 247 participants were included. Primary outcomes included changes in BMI SDS, BMI, and body weight, and secondary outcomes included fasting serum insulin, HbA1c, fasting plasma glucose, SBP, DSP, and safety outcomes.

Results

The meta-analysis included five randomized controlled trials with 247 participants evaluating liraglutide in pediatric obesity. Liraglutide significantly reduced BMI SDS, with a pooled mean difference of −0.17 (p = 0.003), BMI (mean difference: 1.28, p = 0.0008), and body weight (mean difference: 1.83, p = 0.03). Secondary outcomes showed significant reductions in fasting serum insulin levels (pooled effect size: 0.39, p < 0.00001), but no significant effects were observed for DSP (p = 0.29), fasting plasma glucose (p = 0.07), HbA1c (p = 0.09), or systolic blood pressure (p = 0.09). Safety analysis revealed a higher incidence of adverse events in the treatment group (risk ratio: 1.25, p = 0.18), but no significant differences were found in serious adverse events or adverse events leading to therapy discontinuation.

Conclusions

Liraglutide is effective in reducing BMI SDS, BMI, and body weight in pediatric obesity. While it significantly reduces fasting serum insulin levels, other secondary outcomes did not show significant changes. The safety profile of liraglutide shows a higher incidence of adverse events but no increase in serious adverse events or discontinuation rates. These findings support liraglutide's role as an effective and manageable treatment option for pediatric obesity.

查看原文本刊更多论文

利拉鲁肽治疗儿童肥胖的有效性和安全性：随机对照试验的系统评价和meta分析

利拉鲁肽是一种GLP-1受体激动剂，已被研究用于治疗儿童肥胖的潜在益处。本荟萃分析旨在评估利拉鲁肽与安慰剂在儿童肥胖人群中的疗效和安全性。方法系统检索PubMed、Embase和Cochrane关于利拉鲁肽治疗儿童肥胖的随机对照试验（rct）。5项研究共纳入247名参与者。主要结局包括BMI SDS、BMI和体重的变化，次要结局包括空腹血清胰岛素、HbA1c、空腹血糖、收缩压、DSP和安全性结局。结果荟萃分析包括5项随机对照试验，247名参与者评估利拉鲁肽在儿童肥胖中的作用。利拉鲁肽显著降低BMI SDS，合并平均差异为- 0.17 (p = 0.003)， BMI（平均差异为1.28,p = 0.0008）和体重（平均差异为1.83,p = 0.03）。次要结局显示空腹血清胰岛素水平显著降低(合并效应值：0.39,p <；0.00001)，但对DSP （p = 0.29）、空腹血糖（p = 0.07）、糖化血红蛋白（p = 0.09）或收缩压（p = 0.09）均无显著影响。安全性分析显示，治疗组不良事件发生率较高（风险比：1.25,p = 0.18），但严重不良事件或不良事件导致停药的发生率无显著差异。结论司拉鲁肽能有效降低小儿肥胖患者的BMI SDS、BMI和体重。虽然它显著降低了空腹血清胰岛素水平，但其他次要结果没有显示出显著变化。利拉鲁肽的安全性显示不良事件发生率较高，但严重不良事件或停药率未增加。这些发现支持利拉鲁肽作为儿童肥胖有效和可控的治疗选择的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Obesity Medicine Medicine-Public Health, Environmental and Occupational Health

CiteScore

5.50

自引率

0.00%

发文量

审稿时长

40 days

期刊介绍： The official journal of the Shanghai Diabetes Institute Obesity is a disease of increasing global prevalence with serious effects on both the individual and society. Obesity Medicine focusses on health and disease, relating to the very broad spectrum of research in and impacting on humans. It is an interdisciplinary journal that addresses mechanisms of disease, epidemiology and co-morbidities. Obesity Medicine encompasses medical, societal, socioeconomic as well as preventive aspects of obesity and is aimed at researchers, practitioners and educators alike.